New cancer combo drug tested in tiny safety study

NCT ID NCT06894771

Completed Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tested the safety of an experimental drug called MK-4700, given alone or with the approved immunotherapy Keytruda, in 5 people with advanced solid tumors that had stopped responding to other treatments. The main goal was to find a safe dose and see how the body handles the drug. Because it's a Phase 1 trial with very few participants, it cannot tell us if the drug works against cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MK-4700 (an experimental biologic) and pembrolizumab (Keytruda)
What this could lead to: If successful, this could point toward a safe dose of MK-4700 for further testing in larger cancer trials.
What could go wrong: This is a very early, small study (only 5 people) focused on safety, not effectiveness. The drug may not work or could have serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer cervical cancer head and neck squamous cell carcinoma melanoma neoplasm non-small cell lung carcinoma renal cell carcinoma Squamous Cell Carcinoma of Head and Neck transitional cell carcinoma triple-negative breast carcinoma urothelial carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT NEOPLASM

Contacts and locations

Locations

Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0102)

Québec, Quebec, G1J 1Z4, Canada
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0301)

Hackensack, New Jersey, 07601, United States
NEXT Oncology ( Site 0300)

San Antonio, Texas, 78229, United States
Princess Margaret Cancer Center ( Site 0101)

Toronto, Ontario, M5G 2M9, Canada
Rabin Medical Center ( Site 0202)

Petah Tikva, 4941492, Israel
Rambam Health Care Campus ( Site 0201)

Haifa, 3109601, Israel
Sheba Medical Center ( Site 0200)

Ramat Gan, 5265601, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.